Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinal Vessel Response to Lucentis in BRVO
NCT01027481Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Dec 2007
- Primary completion
- Nov 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in branch retinal vein occlusion (BRVO), sponsored by Medical University of Vienna. Started Dec 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT01027481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01027481.